- Home
- Products
- Customized FluoroAb™
- EDNRB
- Anti-EDNRB MAb (Clone 2)-iFluor® 440 Succinimidyl Ester
Anti-EDNRB MAb (Clone 2)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS5144)
- TARGET
- ANTIBODY
- DYE
- Name
- EDNRB
- Alternative Names
- EDNRB; Endothelin receptor type B
- Overview
- Anti-EDNRB Antibody (Clone 2)
- Species Reactivity
- Human
- Name
- iFluor® 440 Succinimidyl Ester
- Color
- Green
- Excitation⁄Emission (nm)
- 434/480
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS5144. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-565 | Anti-EDNRB-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-601 | Anti-EDNBR-VC-MMAE ADC-1 | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-536 | Anti-EDNRB (endothelin B)-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD2 MAb (Clone 7)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2642)
- Altumomab-iFluor 532 (CAT#: ADC-FL-940)
- Anti-TNF MAb (Clone 15)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS6130)
- Anti-CCL11 MAb (Clone 2)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS3909)
- Anti-VEGFA MAb (Clone 7)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10774)
- Anti-CD22 MAb (Clone 18)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS11247)
- Anti-DLL3 MAb (Clone 1)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS7978)
- Anti-CEACAM5 MAb (Clone 2)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS473)
- Anti-CEACAM8 MAb (Clone 1)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS9989)
- Anti-MET MAb (Clone 17)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2948)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
